(12) Patent Application Publication (10) Pub. No.: US 2016/0361298 A1 Novick Et Al

Total Page:16

File Type:pdf, Size:1020Kb

(12) Patent Application Publication (10) Pub. No.: US 2016/0361298 A1 Novick Et Al US 20160361298A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0361298 A1 Novick et al. (43) Pub. Date: Dec. 15, 2016 (54) METHODS AND COMPOSITIONS FOR A63/496 (2006.01) TREATING CANCER A 6LX 39/395 (2006.01) (71) Applicant: Globavir BioSciences, Inc., Los Altos, A63/496 (2006.01) CA (US) A63L/452 (2006.01) A6II 45/06 (2006.01) (72) Inventors: Paul Novick, San Francisco, CA (US); C07K 6/28 (2006.01) Jonathan Choy, Lafayette, CA (US); A6II 3/478 (2006.01) Sumit Mahajan, Foster City, CA (US); Ritika Prasad, Mountain View, CA A6II 3/167 (2006.01) (US); Shalabh Gupta, Mountain View, (52) U.S. Cl. CA (US) CPC ....... A61K 31/4174 (2013.01); A61K 31/41 78 (2013.01); A61K 31/4184 (2013.01); A61 K (21) Appl. No.: 15/179,764 3 1/496 (2013.01); A61K 31/167 (2013.01); (22) Filed: Jun. 10, 2016 A61K 31/4196 (2013.01); A61K 31/4152 (2013.01); A61K 45/06 (2013.01); C07K Related U.S. Application Data 16/2818 (2013.01); A61K 39/3955 (2013.01); (60) Provisional application No. 62/174,430, filed on Jun. A6 IK 2039/505 (2013.01) 11, 2015, provisional application No. 62/174,424, filed on Jun. 11, 2015, provisional application No. (57) ABSTRACT 62/188.413, filed on Jul. 2, 2015, provisional appli cation No. 62/195,750, filed on Jul. 22, 2015. Described are compositions and methods for treating cancer. Some methods comprise the administration of an effective Publication Classification amount of at least one inhibitor of tryptophan 2,3-dioxy (51) Int. Cl. genase (TDO) and/or indoleamine 2,3-dioxygenase (IDO), A6 IK 3/474 (2006.01) optionally combined with one or more additional anti-cancer A6 IK3I/484 (2006.01) agents. Patent Application Publication Dec. 15, 2016 Sheet 1 of 7 US 2016/0361298 A1 FIG. -- on M w * ioconazole X :1 * Deferasiox - or Nicosanide ^x to 8x Etrorro ag orcentration. -1 * Suicorazoie - Cocorazoie * - * vicaras2& 20 Coacetratio: vi Patent Application Publication Dec. 15, 2016 Sheet 2 of 7 US 2016/0361298 A1 FG 2 Wiate CD4+ T Cels u-- r Eltrombopag at 1M * Nicosamide Deferasirox * Tioconazole Concentiation at e : () on M s * Suiconazole S3 * Coconazole * Miconazole Concentratifs ... if Patent Application Publication Dec. 15, 2016 Sheet 3 of 7 US 2016/0361298 A1 FIG. 3 C88CO4- Ces -1 Eitrombopag / * Tioconazole 5 1 * Deferasirax . - Nicosamide - - - 1MT 2 Concentration - if t x -" * Miconazole - * Sulconazole 11 Cioconazole s 3. s Concertrait a Patent Application Publication Dec. 15, 2016 Sheet 4 of 7 US 2016/0361298 A1 FG, 4. C7-CD4+ T Ces r Eltrombopag /* Tioconazole 5 - * Deferasirox - * Nicosamide - or M 2} 40 Concentration -- ty as x - * Nicoagie r a (e Sulconazole s 50 Š r - Coconazole st n 9. 4- the Mi 20 40 6 Concentration -- Patent Application Publication Dec. 15, 2016 Sheet 5 of 7 US 2016/0361298 A1 F.G. 5 Wiate C3 Ces A at Mr * Nicosamide * Deferasirox ?2 ioconazole - Etrombopag 2. forcentratief -- tal s É e - she s S. 1 + Cocorazos XX - * Suiconazole 8 -- * Miconazole . Concentration w ti Patent Application Publication Dec. 15, 2016 Sheet 6 of 7 US 2016/0361298 A1 E.G. 6 CS-58 is & - Fioconazole k1 - * Deferasirox " + Nicosamide -- Eitrombopagy 2 Concertation a 1- * iconazole - Suiconazole - Cioconazole 43 (Concentration or us Patent Application Publication Dec. 15, 2016 Sheet 7 of 7 US 2016/0361298 A1 FG. 7 CB7-08 Ces - -* Tioconazole - * Deferasiox - * Nicosamide s r Eltrombopag 28 43 Concentratic t s *-* iconazole " * Suiconazole 3. 4- Coconazole e s 5 Š ae wet n 3. Concentratio -- i. US 2016/0361298 A1 Dec. 15, 2016 METHODS AND COMPOSITIONS FOR tered to the individual. In some embodiments, miconazole or TREATING CANCER a pharmaceutically acceptable salt or Solvate of miconazole is administered to the individual. In some embodiments, CROSS-REFERENCE TO RELATED Sertaconazole or a pharmaceutically acceptable salt or Sol APPLICATIONS vate of sertaconazole is administered to the individual. In 0001. This application claims the benefit of U.S. Provi Some embodiments, tioconazole or a pharmaceutically sional Application No. 62/174,430 filed Jun. 11, 2015; U.S. acceptable salt or Solvate oftioconazole is administered to Provisional Application No. 62/174,424 filed Jun. 11, 2015: the individual. In some embodiments, fenticonazole or a U.S. Provisional Application No. 62/188,413 filed Jul. 2, pharmaceutically acceptable salt or Solvate offenticonazole is administered to the individual. In some embodiments, 2015; and U.S. Provisional Application No. 62/195,750 filed liaroZole or a pharmaceutically acceptable salt or Solvate of Jul. 22, 2015; the entirety of which are incorporated by liarozole is administered to the individual. In some embodi reference herein. ments, cloconazole or a pharmaceutically acceptable salt or BACKGROUND solvate of cloconazole is administered to the individual. In Some embodiments, itraconazole or a pharmaceutically 0002 Immuno-oncology focuses on the development and acceptable salt or Solvate of itraconazole is administered to delivery of therapies that improve a body's intrinsic poten the individual. In some embodiments, niclosamide or a tial for generating an effective immune response against pharmaceutically acceptable salt or Solvate of niclosamide is cancer. Immuno-oncology therapies often target the immune administered to the individual. In some embodiments, system and not the cancer, providing the potential to treat deferasiroX or a pharmaceutically acceptable salt or Solvate cancer across a variety of tumor types. Manipulation of of deferasirox is administered to the individual. In some T-cell modulation is one method of augmenting the immune embodiments, eltrombopag or a pharmaceutically accept system to treat cancer. able salt or solvate of eltrombopag is administered to the individual. In some embodiments, the cancer comprises SUMMARY OF THE INVENTION colon cancer, pancreatic cancer, cutaneous T-cell lymphoma, 0003. The immune system has an intrinsic potential for glioma, head and neck cancer, hepatocarcinoma, leukemia, recognizing and eliminating tumor cells. However, tumors glioblastoma, colorectal cancer, gallbladder, mastocytoma, can adapt and circumvent the immune system by disrupting acute myeloid leukemia, adrenocortical cancer, bladder T-cell checkpoint pathways. An approach to disrupt tumor urothelial cancer, brain tumor, brain lower grade glioma, inhibition of the immune system involves the targeted block breast cancer, breast invasive cancer, cervical cancer, cho of checkpoint pathways Immune checkpoint pathway targets langiocarcinoma, cutaneous melanoma, diffuse large B-cell for activating therapeutic antitumor immunity include pro lymphoma, endometrial cancer, glioblastoma multiform, grammed cell death protein (PD-1) and its ligand PD-L1, H&N squamous cell carcinoma, hepatocellular carcinoma, indoleamine 2,3-dioxygenase (IDO), and cytotoxic T-lym kidney chromophobe carcinoma, lung cancer, lung adeno phocyte antigen 4 (CTLA-4). IDO is a heme-containing carcinoma, lung Squamous cell carcinoma, mesothelioma, enzyme that catalyzes the oxidation of L-tryptophan to ovarian serous cystadenocarcinoma, pancreatic adenocarci N-formyl-L-kynurenine. Another heme-containing enzyme noma, pheochromocytoma and paraganglioma, prostate that also catalyzes tryptophan degradation is tryptophan adenocarcinoma, prostate cancer, rectum adenocarcinoma, 2,3-dioxygenase (TDO). TDO has been found to be rectum cancer, renal cell cancer, renal papillary cell cancer, expressed in many tumors and this expression prevents sarcoma, testicular germ cell tumors, thymoma, thyroid tumor rejection by locally depleting tryptophan. Develop cancer, uterine carcinosarcoma, melanoma, uveal mela ment of TDO inhibitors for the treatment of tumors is an noma, or a combination thereof. In some embodiments, the active area of drug development. As the active sites of both effective amount is from about 5 mg to about 5,000 mg. In IDO and TDO enzymes are structurally similar, various Some embodiments, the individual is administered an addi inhibitors of TDO and IDO have activity against one tional active agent comprising a PD-1/PD-L pathway inhibi another. Provided in this disclosure are compounds and tor, IDO inhibitor, TDO inhibitor, CTLA-4 inhibitor, or a compositions comprising TDO inhibitors, IDO inhibitors, combination thereof. In some embodiments, the individual is and inhibitors of both TDO and IDO for active stimulation administered an additional active agent comprising BMS of the immune system. In various aspects, provided are TDO 936559, MEDI4736, MPDL3280A, MSB0010718C, AMP inhibitors, IDO inhibitors, and inhibitors of both TDO and 224, nivolumab, pembrolizumab, pidilizumab, BMS IDO that are useful for the treatment of cancer. 98.6016, MDX1105-01, avelumab, indoximod, F001287, 0004. In one aspect, provided herein is a method of NLG919, INCB024360, ipilimumab, tremelimumab, anti treating cancer comprising administering to an individual in body clone 9H10, antibody clone BNI3, Del 60, M9-14 del need thereof an effective amount of econazole, Sulconazole, 55, or a salt, solvate or combination thereof. In some isoconazole, miconazole, Sertaconazole, tioconazole, fenti embodiments, the method further comprises treating the conazole, liarozole, cloconazole, itraconazole, niclosamide, individual with an immunotherapy. In some embodiments, deferasiroX, eltrombopag, or a pharmaceutically acceptable the method further comprises treating the individual with a salt, Solvate, or combination thereof. In some embodiments, chimeric antigen receptor (CAR) T-cell therapy. In some econazole or
Recommended publications
  • Universidade Federal Da Paraíba Centro De Ciências Da Saúde
    Universidade Federal da Paraíba Centro de Ciências da Saúde Programa de Pós-Graduação em Produtos Naturais e Sintéticos Bioativos Wylly Araújo de Oliveira Atividade do óleo essencial de Cymbopogon winterianus Jowitt ex Bor contra Candida albicans , Aspergillus flavus e Aspergillus fumigatus João Pessoa-PB 2011 Wylly Araújo de Oliveira Atividade do óleo essencial de Cymbopogon winterianus Jowitt ex Bor contra Candida albicans , Aspergillus flavus e Aspergillus fumigatus Tese de doutorado apresentada ao Programa de Pós-Graduação em Produtos Naturais e Sintéticos Bioativos, Centro de Ciências da Saúde, Universidade Federal da Paraíba, em cumprimento aos requisitos necessários para a obtenção do título de Doutor em Produtos Naturais e Sintéticos Bioativos, área de concentração: farmacologia Orientadora: Prof.ª Dr.ª Edeltrudes de Oliveira Lima João Pessoa-PB 2011 Wylly Araújo de Oliveira Atividade do óleo essencial de Cymbopogon winterianus Jowitt ex Bor contra Candida albicans, Aspergillus flavus e Aspergillus fumigatus Tese de Doutorado aprovada em 22/06/2011 Banca examinadora ________________________________________________ Prof.ª Dr.ª Edeltrudes de Oliveira Lima Orientadora/UFPB _________________________________________________ Prof.ª Dr.ª Hilzeth de Luna Freire Pessôa - UFPB _________________________________________________ Prof. Dr. José Pinto de Siqueira Júnior - UFPB __________________________________________________ Prof.ª Dr.ª Margareth de Fátima Formiga Melo Diniz - UFPB __________________________________________________ Prof. Dr. Thompson Lopes de Oliveira - UFPB Dedicatória Com amor, dedico este trabalho à minha família: a meu pai, Francisco Claro de Oliveira; a minha mãe, Maria Araújo Filha; e a meus irmãos Kylly Araújo de Oliveira e Welly Araújo de Oliveira. Sem o apoio deles, nada disso teria sido possível. Apesar da ausência, eles sempre estiveram no meu coração.
    [Show full text]
  • (Trulicity) Pen and the Semaglutide (Ozempic) Pen
    Protocol H9X-MC-B021(b) Crossover Study Comparing Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen NCT03724981 Approval Date: 30-Nov-2018 H9X-MC-B021(b) Clinical Protocol Page 1 Protocol H9X-MC-B021(b): Crossover Study Comparing the Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen Confidential Information The information contained in this document is confidential and is intended for the use of clinical investigators. It is the property of Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical investigation of dulaglutide (LY2189265), unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its subsidiaries. Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries. Dulaglutide (LY2189265) Eli Lilly and Company Indianapolis, Indiana USA 46285 Protocol Electronically Signed and Approved by Lilly on 07 Aug 2018 Amendment (a) Electronically Signed and Approved by Lilly on 11 Sep 2018 Amendment (b) Electronically Signed and Approved by Lilly on date below Approval Date: 30-Nov-2018 GMT LY2189265 H9X-MC-B021(b) Clinical Protocol Page 2 Table of Contents Section Page Protocol H9X-MC-B021(b): Crossover Study Comparing the Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen ............................................................1 Table of Contents........................................................................................................................2 1.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Two Inhibitors of Yeast Plasma Membrane Atpase 1 (Scpma1p): Toward the Development of Novel Antifungal Therapies Sabine Ottilie1†, Gregory M
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by D-Scholarship@Pitt Ottilie et al. J Cheminform (2018) 10:6 https://doi.org/10.1186/s13321-018-0261-3 RESEARCH ARTICLE Open Access Two inhibitors of yeast plasma membrane ATPase 1 (ScPma1p): toward the development of novel antifungal therapies Sabine Ottilie1†, Gregory M. Goldgof1,4†, Andrea L. Cheung1, Jennifer L. Walker2, Edgar Vigil1, Kenneth E. Allen3, Yevgeniya Antonova‑Koch1, Carolyn W. Slayman3^, Yo Suzuki4 and Jacob D. Durrant2* Abstract Given that many antifungal medications are susceptible to evolved resistance, there is a need for novel drugs with unique mechanisms of action. Inhibiting the essential proton pump Pma1p, a P-type ATPase, is a potentially efective therapeutic approach that is orthogonal to existing treatments. We identify NSC11668 and hitachimycin as structur‑ ally distinct antifungals that inhibit yeast ScPma1p. These compounds provide new opportunities for drug discovery aimed at this important target. Keywords: Antifungal, PMA1, P-type ATPase, Computer modeling, Saccharomyces cerevisiae, In vitro evolution, Drug resistance Background sterol-C-24-methyltransferase and the fungal cell mem- Antifungal medications are in high demand, but low brane directly [8]. efcacy, host toxicity, and emerging resistance among Only a few approved antimycotics have mecha- clinical strains [1, 2] complicate their use. Tere is an nisms that are unrelated to ergosterol biosynthesis. urgent need for novel antimycotic therapeutics with For example, the highly efective echinocandins inhibit unique mechanisms of action. Te purpose of the cur- 1,3-β-glucan synthase, hindering production of the criti- rent work is to describe two novel antifungals: 4-N,6- cal cell-wall component β-glucan [9, 10]; and the terato- N-bis(3-chlorophenyl)-1-methylpyrazolo[3,4-d] genic compound fucytosine interferes with eukaryotic pyrimidine-4,6-diamine (NSC11668), and hitachimycin RNA/DNA synthesis [11, 12].
    [Show full text]
  • Sulfonylurea Review
    Human Journals Review Article February 2018 Vol.:11, Issue:3 © All rights are reserved by Farah Yousef et al. Sulfonylurea Review Keywords: Type II diabetes, Sulfonylurea, Glimipiride, Glybu- ride, Structure Activity Relationship. ABSTRACT Farah Yousef*1, Oussama Mansour2, Jehad Herbali3 Diabetes Mellitus is a chronic disease represented with high 1 Ph.D. candidate in pharmaceutical sciences, Damas- glucose blood levels. Although sulfonylurea compounds are the cus University, Damascus, Syria. second preferred drug to treat Type II Diabetes (TYIID), they are still the most used agents due to their lower cost and as a 2 Assistant Professor in pharmaceutical chimestry, Ti- mono-dosing. Literature divides these compounds according to st nd rd shreen University, Lattakia, Syria their discovery into 1 , 2 , 3 generations. However, only six sulfonylurea compounds are now available for use in the United 3 Assistant Professor in pharmaceutical chimestry, Da- States: Chlorpropamide, Glimepiride, Glipizide, Glyburide, mascus University, Damascus, Syria. Tolazamide, and Tolbutamide. They function by increasing Submission: 24 January 2018 insulin secretion from pancreatic beta cells. Their main active site is ATP sensitive potassium ion channels; Kir 6.2\SUR1; Accepted: 29 January 2018 Published: 28 February 2018 Potassium Inward Rectifier ion channel 6.2\ Sulfonylurea re- ceptor 1. They are sulfonamide derivatives. However, research- ers have declared that sulfonylurea moiety is not the only one responsible for this group efficacy. It has been known that sud- den and acute hypoglycemia incidences and weight gain are the www.ijppr.humanjournals.com two most common adverse effects TYIID the patient might face during treatment with sulfonylurea agents. This review indi- cates the historical development of sulfonylurea and the differ- ences among this group members.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • WO 2019/090111 Al 09 May 2019 (09.05.2019) W 1P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2019/090111 Al 09 May 2019 (09.05.2019) W 1P O PCT (51) International Patent Classification: (84) Designated States (unless otherwise indicated, for every A61K 31/7064 (2006.01) A61P 33/14 (2006.01) kind of regional protection available): ARIPO (BW, GH, A61K 45/06 (2006.01) A61P 25/28 (2006.01) GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, A61P 35/00 (2006.01) C07F 9/6561 (2006.01) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, A61P 31/12 (2006.01) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, ΓΕ , IS, IT, LT, LU, LV, (21) International Application Number: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, PCT/US20 18/059004 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (22) International Filing Date: KM, ML, MR, NE, SN, TD, TG). 02 November 2018 (02. 11.2018) Declarations under Rule 4.17: (25) Filing Language: English — as to applicant's entitlement to apply for and be granted a (26) Publication Language: English patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of the (30) Priority Data: earlier application (Rule 4.17(Hi)) 62/581,574 03 November 2017 (03. 11.2017) US 62/664,841 30 April 2018 (30.04.2018) US Published: — with international search report (Art.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Us 2017 / 0239276 A1
    US 20170239276A1 ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2017/ 0239276 A1 MUTLU et al. ( 43 ) Pub . Date: Aug . 24 , 2017 ( 54 ) PHARMACEUTICAL COMBINATIONS OF ( 30 ) Foreign Application Priority Data SITAGLIPTIN Sep. 5 , 2014 ( TR ) .. .. .. .. .. 2014 / 10448 (71 ) Applicant : SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI, Publication Classification ISTANBUL ( TR ) (51 ) Int. Cl. ( 72 ) Inventors : ONUR MUTLU , ISTANBUL ( TR ) ; A61K 31/ 64 (2006 .01 ) ALI TÜRKYILMAZ , ISTANBUL A61K 9 / 20 ( 2006 . 01 ) ( TR ) ; GÜLAY YELKEN , ISTANBUL A61K 9 / 28 ( 2006 . 01 ) ( TR ); MEHTAP SAYDAM , A61K 31/ 4985 ( 2006 . 01 ) ISTANBUL ( TR ) (52 ) U . S . CI. CPC .. .. .. A61K 31 /64 ( 2013 .01 ) ; A61K 31 /4985 ( 21 ) Appl. No. : (2013 .01 ) ; A61K 9 / 2027 ( 2013 .01 ) ; A61K 15 / 507, 946 9 /2054 ( 2013 .01 ) ; A61K 9 / 28 (2013 .01 ) ( 22 ) PCT Filed : Sep . 4 , 2015 (57 ) ABSTRACT (86 ) PCT NONo . : PCT /EP2015 /070251 A pharmaceutical combination comprising sitagliptin or a $ 371 ( c ) ( 1 ) , pharmaceutically acceptable salt thereof in combination ( 2 ) Date : Mar. 1 , 2017 with a sulfonylurea . US 2017 /0239276 A1 Aug . 24 , 2017 PHARMACEUTICAL COMBINATIONS OF 4 - ( 2 , 4 , 5 - trifluorophenyl) butan - 1 - one or (2R ) - 4 - oxo - 4 - [ 3 SITAGLIPTIN ( trifluoromethyl) - 5 ,6 - dihydro [ 1, 2 , 4 ] triazolo [ 4 , 3 - a ]pyrazin FIELD OF INVENTION 7 (8H )- yl )- 1 - ( 2 ,4 ,5 -trifluorophenyl ) butan - 2 - amine) and its [0001 ] The present invention relates to a pharmaceutical chemical structure is shown in the Formula I . combination comprising sitagliptin or a pharmaceutically [0004 ] Sitagliptin is licensed in the US and EU under the acceptable salt thereof in combination with a sulfonylurea name of JANUVIA in the strength of 100 mg, 50 mg, and 25 and at least one pharmaceutically acceptable excipient.
    [Show full text]
  • WO 2015/134796 Al 11 September 2015 (11.09.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/134796 Al 11 September 2015 (11.09.2015) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 9/14 (2006.01) A61K 47/10 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 9/16 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US20 15/0 19042 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 5 March 2015 (05.03.2015) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 61/948,173 5 March 2014 (05.03.2014) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 14/307,138 17 June 2014 (17.06.2014) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicant: PROFESSIONAL COMPOUNDING CEN¬ LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, TERS OF AMERICA [US/US]; 9901 South Wilcrest SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Drive, Houston, TX 77099 (US).
    [Show full text]
  • Multidrug Treatment with Nelfinavir and Cepharanthine Against COVID-19
    Supplemental Information Multidrug treatment with nelfinavir and cepharanthine against COVID-19 Hirofumi Ohashi1,2,¶, Koichi Watashi1,2,3,4*, Wakana Saso1,5.6,¶, Kaho Shionoya1,2, Shoya Iwanami7, Takatsugu Hirokawa8,9,10, Tsuyoshi Shirai11, Shigehiko Kanaya12, Yusuke Ito7, Kwang Su Kim7, Kazane Nishioka1,2, Shuji Ando13, Keisuke Ejima14, Yoshiki Koizumi15, Tomohiro Tanaka16, Shin Aoki16,17, Kouji Kuramochi2, Tadaki Suzuki18, Katsumi Maenaka19, Tetsuro Matano5,6, Masamichi Muramatsu1, Masayuki Saijo13, Kazuyuki Aihara20, Shingo Iwami4,7,21,22,23, Makoto Takeda24, Jane A. McKeating25, Takaji Wakita1 1Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan, 2Department of Applied Biological Science, Tokyo University of Science, Noda 278-8510, Japan, 3Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan, 4MIRAI, JST, Saitama 332-0012, Japan, 5The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan, 6AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan, 7Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka 812-8581, Japan, 8Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064, Japan, 9Division of Biomedical Science, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan, 10Transborder Medical Research Center, University of Tsukuba, Tsukuba 305-8575, Japan, 11Faculty of Bioscience, Nagahama Institute
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]